Search

Specifically, we wanted to estimate the number of treatment lines received during 20-year follow-up to determine the number of MCL patients that could potentially receive novel, targeted therapies during the follow-up period. B Background: b Mantle cell lymphoma (MCL) is a rare subtype of B-cell lymphoma that is currently considered incurable, yet treatable condition with increasing amount of treatment options. At 10 years of simulated follow-up, 525 (95.8%) patients had received first-line therapy, 307 (56.0%) had received second-line therapy, 148 (27.0%) had received third-line therapy and 64 (11.7%) had received fourth-line therapy. [Extracted from the article]

Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020., (© 2025 John Wiley & Sons Ltd.)